AAPL347.96+3.97 (+1.15%) ▲|ABBV284.63-0.17 (-0.06%) ▼|ABT102.52+2.01 (+2.00%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.60+3.96 (+2.23%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.07+1.46 (+0.45%) ▲|BA187.53-4.75 (-2.47%) ▼|BAC51.10+0.32 (+0.63%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.54-12.06 (-1.05%) ▼|BMY63.01+1.89 (+3.09%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B547.00+8.01 (+1.49%) ▲|C122.56-1.29 (-1.04%) ▼|CAT703.84-36.38 (-4.91%) ▼|CL97.40+4.00 (+4.28%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.44-3.22 (-1.56%) ▼|COP145.64-0.03 (-0.02%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.24+8.46 (+3.50%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.49+1.71 (+1.84%) ▲|CVX226.65-0.13 (-0.06%) ▼|DE643.60+7.06 (+1.11%) ▲|DHR229.88-3.98 (-1.70%) ▼|DIS113.14+1.31 (+1.17%) ▲|DUK125.42+4.75 (+3.94%) ▲|EMR160.26-2.85 (-1.75%) ▼|FDX303.99+5.76 (+1.93%) ▲|GD350.76+6.05 (+1.75%) ▲|GE293.51-2.37 (-0.80%) ▼|GEV827.38-98.55 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.22+1.11 (+1.46%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.27-13.45 (-1.49%) ▼|HD327.66+13.52 (+4.30%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.19+0.73 (+0.29%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.68+9.90 (+3.84%) ▲|JPM336.51+1.32 (+0.39%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.74+35.99 (+2.83%) ▲|LMT590.20+38.69 (+7.01%) ▲|LOW204.39+7.83 (+3.98%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA632.81+10.19 (+1.64%) ▲|MCD252.55+6.30 (+2.56%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.58+3.55 (+3.82%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.54+0.80 (+0.46%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.25-2.63 (-1.75%) ▼|MS183.94-3.08 (-1.64%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.91+3.63 (+4.64%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.31+0.78 (+2.08%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.52-3.62 (-2.80%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.41+0.56 (+1.88%) ▲|PG165.60+8.76 (+5.59%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.76+4.30 (+2.18%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.55-17.47 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|AAPL347.96+3.97 (+1.15%) ▲|ABBV284.63-0.17 (-0.06%) ▼|ABT102.52+2.01 (+2.00%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.60+3.96 (+2.23%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.07+1.46 (+0.45%) ▲|BA187.53-4.75 (-2.47%) ▼|BAC51.10+0.32 (+0.63%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.54-12.06 (-1.05%) ▼|BMY63.01+1.89 (+3.09%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B547.00+8.01 (+1.49%) ▲|C122.56-1.29 (-1.04%) ▼|CAT703.84-36.38 (-4.91%) ▼|CL97.40+4.00 (+4.28%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.44-3.22 (-1.56%) ▼|COP145.64-0.03 (-0.02%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.24+8.46 (+3.50%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.49+1.71 (+1.84%) ▲|CVX226.65-0.13 (-0.06%) ▼|DE643.60+7.06 (+1.11%) ▲|DHR229.88-3.98 (-1.70%) ▼|DIS113.14+1.31 (+1.17%) ▲|DUK125.42+4.75 (+3.94%) ▲|EMR160.26-2.85 (-1.75%) ▼|FDX303.99+5.76 (+1.93%) ▲|GD350.76+6.05 (+1.75%) ▲|GE293.51-2.37 (-0.80%) ▼|GEV827.38-98.55 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.22+1.11 (+1.46%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.27-13.45 (-1.49%) ▼|HD327.66+13.52 (+4.30%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.19+0.73 (+0.29%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.68+9.90 (+3.84%) ▲|JPM336.51+1.32 (+0.39%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.74+35.99 (+2.83%) ▲|LMT590.20+38.69 (+7.01%) ▲|LOW204.39+7.83 (+3.98%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA632.81+10.19 (+1.64%) ▲|MCD252.55+6.30 (+2.56%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.58+3.55 (+3.82%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.54+0.80 (+0.46%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.25-2.63 (-1.75%) ▼|MS183.94-3.08 (-1.64%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.91+3.63 (+4.64%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.31+0.78 (+2.08%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.52-3.62 (-2.80%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.41+0.56 (+1.88%) ▲|PG165.60+8.76 (+5.59%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.76+4.30 (+2.18%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.55-17.47 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|
19.5 C
New York
Thursday, October 22, 2026

Tag: drug design

newsFORsourcecompanycontentinformation1releasesmarket

Evaxion receives Prix Galien UK Award for Best digital health solution

COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on...

Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel

SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

【COMPUTEX 2026】Compal Integrates Quantum Technology and AI – Partnering with Top Universities and Pharmaceutical Firms to Build a Biotech AI Platform

TAIPEI, June 4, 2026 /PRNewswire/ -- Compal Electronics (Compal; TWSE: 2324) showcases its landmark achievements in Quantum Technology and Advanced Artificial Intelligence (AI) at COMPUTEX...

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR...

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Blacksmith Medicines Co-Founder Presents at the 21st International Conference on Biological Inorganic Chemistry

Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Blacksmith Medicines,...

Atombeat and BioDuro Announce Strategic Partnership to Launch an AI-Powered Platform for Accelerated Peptide Drug Discovery

SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- On July 30, 2025, Atombeat Inc., a leading force in AI for drug discovery, and BioDuro, a...

VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration

VedTechBio enhances RxAgentAI platform; teams with US-based AlphaMeld to cut drug discovery time and co-develop therapies for rare and metabolic diseases.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug design

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers